Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza vs Durezol after cataract surgery and MIGS
NCT04687800Phase 4Terminated
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in cataract and primary open-angle glaucoma (POAG) (2 arms). Primary endpoint: Intraocular Pressure at 30 days. Started Dec 2020; status: terminated.
02
Drugs
ozurdex
03
Conditions
cataractprimary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT04687800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687800.